Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. 

The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Cystic Fibrosis Foundation

Cystic Fibrosis Trust

Imperial Innovations

IP Group

Epidarex Capital

Forbion Capital Partners

Novartis Venture Fund

Versant Ventures

Enterprise Therapeutics

#CysticFibrosis affects over 10,800 people in the UK, with one in 25 of us carrying the #gene #mutation that causes it, often without knowing.

Join us for #CFWeek to raise awareness and celebrate the #innovative progress that the #scientific community has already made in #CF #research, #drugdiscovery and #drugdevelopment, as well as the exciting breakthroughs on the horizon.

You can get involved with Cystic Fibrosis Trust here: https://rb.gy/li8ux 
#CysticFibrosisAwareness

What is the importance of endpoints in #raredisease #research?
 
In conversation with International Clinical Trials (Samedan Ltd), our CMO, Dr Niyati Prasad shares her insight on conducting #clinicaltrials for rare diseases, from how #researchers can best select primary and secondary endpoints to the role of ePROs.
 
Read the full interview here: https://bit.ly/3C6hZ0p

Every May, the #cysticfibrosis community comes together for #CFAwarenessMonth, with the unified aim to raise #disease awareness and find a cure for all people with #CF.

Joining this mission, Enterprise Therapeutics is dedicated to the #research, development, and delivery of novel muco-regulatory treatments for CF and other #respiratorydiseases. 

Learn more about our approach here: https://bit.ly/3o6E2An

Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK.
 
Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases.
 
Learn more and register here: https://bit.ly/3X0Wh6P #COGUK

Viewport Meta

IPhone / Mobile Compatible

Euro

Apple Mobile Web Clips Icon

Google Font API

WordPress

DoubleClick.Net

reCAPTCHA

Facebook Sharer

WordPress 6.6

John Ford

Project Director

Joanne Charlwood

Office Manager

Rachel Gosling

Head of Biology

Henry Danahay

Chief Scientific Officer, Co-Founder

Martin Gosling

Head of Development

Paul Russell

Chief Information Officer

Steve Collingwood

Rob Woodman

Peter Finan

David Morris

Chief Medical Officer

Amit D. Munshi

Chairman, Board of Directors

Renu Gupta

Niyati Prasad

Janet Hammond

Non-Executive Director

Europe Early Stage Companies With Fewer Than 1000 Employees

United Kingdom Companies With Less Than $500M in Revenue (Top 10K)

United Kingdom Startups Founded in 2014

Europe, Middle East, and Africa (EMEA) Early Stage Companies With Less Than $500M in Revenue

Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Panakes Partners

Series B - Enterprise Therapeutics

Grant - Enterprise Therapeutics

Venture Round - Enterprise Therapeutics

Series A - Enterprise Therapeutics

Falmer

East Sussex

United Kingdom

Europe

Enterprise Therapeutics Publishes on Medicinal Chemistry of ETD001, a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

Enterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Enterprise Therapeutics appoints Dr Renu Gupta as CMO

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive ...

Enterprise Therapeutics Publishes Preclinical Profile of ETD001, a Novel Inhaled ENaC Blocker

A novel inhaled, long-acting ENaC inhibitor aimed at treating all people with cystic fibrosis by increasing hydration and clearance of mucus.

Drugs targeting the underlying mechanisms of mucus congestion to enhance clearance from the airways, applicable to diseases like cystic fibrosis, COPD, and severe asthma.

A portfolio of compounds targeting TMEM16A chloride channels to treat cystic fibrosis and other respiratory diseases, acquired by Roche.

Philippines

Asia

United States

North America

Brazil

South America

Mexico

HTML5

Google Tag Manager

Microsoft Outlook

Bootstrap

Thawte SSL

Office 365

jQuery

Wordpress

GoDaddy Premium DNS

Vimeo

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. They are focused on developing new medicines to treat patients with respiratory diseases such as cystic fibrosis, asthma, and COPD, aiming to improve patient quality of life and reduce the frequency of lung infections.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	1bddd470
crunchbase profile	general	Nov 25, 2024 12:04 PM	62fe50b8
li profile	general	Jan 30, 2024 8:19 PM	d0595de3
translate crunchbase fundingrounds	general	Nov 25, 2024 1:51 PM	a1a9d538
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ENTERPRISETHERAPEUTICS

Enterprise Therapeutics